Jeroen C Verheijen
Overview
Explore the profile of Jeroen C Verheijen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
170
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Durand-Reville T, Comita-Prevoir J, Zhang J, Wu X, May-Dracka T, Romero J, et al.
J Med Chem
. 2020 Jul;
63(21):12511-12525.
PMID: 32658473
Multidrug resistant Gram-negative bacterial infections are an increasing public health threat due to rapidly rising resistance toward β-lactam antibiotics. The hydrolytic enzymes called β-lactamases are responsible for a large proportion...
2.
McKinney D, Zhou F, Eyermann C, Ferguson A, Prince D, Breen J, et al.
ACS Infect Dis
. 2016 Sep;
1(7):310-6.
PMID: 27622821
Bacterially expressed β-lactamases are rapidly eroding the clinical utility of the important β-lactam class of antibacterials, significantly impairing our ability to fight serious bacterial infections. This paper describes a study...
3.
Miller M, Kale M, Reddy K, Tentarelli S, Zambrowski M, Zhang M, et al.
ACS Med Chem Lett
. 2014 Aug;
5(8):915-20.
PMID: 25147614
We present a comprehensive study of C6-alkylidene containing oxapenems. We show that this class of β-lactamase inhibitors possesses an unprecedented spectrum with activity against class A, C, and D enzymes....
4.
Keating T, Lister T, Verheijen J
Pharm Pat Anal
. 2013 Dec;
3(1):87-112.
PMID: 24354981
This article reviews 101 patent applications published in 2011 that disclosed small-molecule antibacterials and reported bacterial growth inhibition, in which the compounds were not similarly disclosed to be toxic to...
5.
Stokes S, Morningstar M, Kocis H, Verheijen J
Pharm Pat Anal
. 2013 Nov;
1(5):601-20.
PMID: 24236928
This review summarizes patent applications from 2010 for small molecules for which there is a claim of antibacterial activity. The primary criterion for inclusion in this analysis was reporting of...
6.
Zask A, Verheijen J, Richard D
Expert Opin Ther Pat
. 2011 May;
21(7):1109-27.
PMID: 21591993
Introduction: The mammalian target of rapamycin (mTOR) is a protein kinase and a key component of the PI3K/Akt/mTOR signaling pathway, and is deregulated in half of all human cancers. Rapamycin...
7.
Richard D, Verheijen J, Zask A
Curr Opin Drug Discov Devel
. 2010 Jul;
13(4):428-40.
PMID: 20597028
mTOR is a serine-threonine kinase that plays a key role in the regulation of cellular growth. The mTOR pathway consists of two distinct complexes: mTOR/Raptor (mTORC1) and mTOR/Rictor (mTORC2). In...
8.
Zask A, Verheijen J, Richard D, Kaplan J, Curran K, Toral-Barza L, et al.
Bioorg Med Chem Lett
. 2010 Mar;
20(8):2644-7.
PMID: 20227881
Incorporation of bridged morpholines in monocyclic triazine PI3K/mTOR inhibitors gave compounds with increased mTOR selectivity relative to the corresponding morpholine analogs. Compounds with ureidophenyl groups gave highly potent and selective...
9.
Richard D, Verheijen J, Yu K, Zask A
Bioorg Med Chem Lett
. 2010 Mar;
20(8):2654-7.
PMID: 20223664
Potent inhibitors of the mammalian target of rapamycin (mTOR) which contain the triazine scaffold and the (R)-3-methyl morpholine moiety have been identified. Such compounds also demonstrated good selectivity over the...
10.
Verheijen J, Richard D, Curran K, Kaplan J, Yu K, Zask A
Bioorg Med Chem Lett
. 2010 Mar;
20(8):2648-53.
PMID: 20223663
Isosteric replacement of one of the 3,5-ethylene-bridged morpholines in 2-arylureidophenyl-4,6-di(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)triazines led to significant improvements in human microsomal stability. 3-R-Me-morpholine and tetrahydropyran were identified as preferred isosteres for the bridged morpholine....